Celgene ACE-536-MDS-002: A phase 3, open-label, randomized study to compare the efficacy and safety of Luspatercept (ACE-536) versus Epoetin Alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naive subjects who require red blood cell transfusions. (COMMANDS)
The main purpose of this study is to see if people with anemia due to MDS will experience a more decreased need for regular blood transfusions if they take luspatercept plus best supportive care compared to epoetin alfa plus best supportive care. They safety of luspatercept compared to the safety of epoetin alfa will also be evaluated in this study.
Principal Investigator
William MacLaughlin, MD
Contact
Ora Mae Jackson, RN, OCN
757-534-5565
[email protected]
Locations
Peninsula Cancer Institute
12100 Warwick Blvd, Suite 201
Newport News, VA 23601
Peninsula Cancer Institute
120 King's Way, Suite 3100
Williamsburg, VA 23185
Peninsula Cancer Institute
7544-B Medical Drive
Gloucester, VA 23061
Cancer Specialists of Tidewater
110-E Wimbledon Square
Chesapeake, VA 23320
Cancer Specialists of Tidewater
1200 First Colonial Road
Virginia Beach, VA 23454
Cancer Specialists of Tidewater
5839 Harbourview Blvd. Suite 100
Suffolk, VA 23435
Status
Recruiting
Category
Oncology
Study #